

**REMARKS/ARGUMENTS**

By the present amendment, applicants have canceled Claims 11, 18, 28, and 32-37. Therefore, the claims remaining for consideration by the Examiner are Claims 1-10, 12-17, 19-27, and 29-31.

The foregoing amendments to the specification are to place the Abstract on a separate sheet. The amendments to the claims are to place the claims in better form and remove multiple dependencies. No new matter has been added. Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7945

  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940

Date: January 31, 2005